Latest From DiagnoCure Inc.
The most popular targets for mergers and acquisitions in the medical device space during 2015 were companies making in-vitro diagnostic tests and cardiovascular technology.
While the PSA test is still widely recognized as a valuable prostate cancer screening tool, its dismal accuracy record has created an acute need for more effective and informative alternatives, and the field of molecular diagnostics, based on gene-based biomarkers, is leading the charge.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Laboratory Testing Services
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- DiagnoCure Inc.
- Senior Management
Yves C Fradet, MD, Pres. & CMO
Frédéric Boivin, Sr. Dir., Fin. & Admin.
- Contact Info
Phone: (418) 527-6100
4535 Wilfrid-Hamel Blvd., Ste. 250
Quebec City, G1P 2J7
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.